Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Aug 15, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,731,126. The patent covers novel technology whereby the Quell® device automatically modulates therapeutic neurostimulation based on the user's sle...
Aug 3, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today reported an agreement with Fukuda Denshi for DPNCheck® distribution in Japan. DPNCheck is NeuroMetrix' rapid, accurate, and quantitative point-of-care test to detect diabetic peripheral neuropathy. Diabetes is a serious health ...
Jul 27, 2017 BOSTON--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported today that it had shipped its 100,000th Quell® wearable device for treatment of chronic pain since commercial launch in mid-2015. Quell device shipments have posted growth in each of the eight sequential quarters that it has been on...
Jul 20, 2017 Revenue of $4.3M is up 63% year-over-year Quell device shipments of 20.1K and electrode reorders of 30.7K represent new quarterly highs DPNCheck revenue of $0.8 million is up 78% year-over-year WALTHAM, Mass.--(BUSINESS WIRE)-- ...
Jul 13, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2017 second quarter financial results before the opening of the market on Thursday July 20, 2017. The Company will host a conference call at 8:00 a.m., Eastern Time on July 20, 2017 to discuss its ...
Jul 10, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ: NURO) announced today that it has entered into a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a private placement of 7,000 shares of Series F convertible preferred stock at a price ...
Jul 6, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that Michael MacDonald has been promoted to SVP and General Manager of Diagnostics. In this role, Mr. MacDonald will oversee the Company's diagnostic products which include DPNCheck® and ADVANCE™. ...
Jun 26, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today provided an update on its data science initiative and the related Quell® Health Cloud. Data science consists of the development of large cloud databases and the use of powerful analytical tools such as machine learning a...
Jun 23, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today provided an update on its Quell® clinical program. Quell is a wearable non-invasive neurostimulator that provides widespread analgesia for chronic pain. In addition to delivery of therapy, the device and its associated smartphone app tr...
Jun 13, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,675,801. The patent covers novel mechanisms to help Quell® users safely obtain pain relief therapy over prolonged time periods. More ...
Jun 8, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and CEO of NeuroMetrix, is scheduled to speak at the upcoming 2017 Marcum Microcap Conference at the Grand Hyatt Hotel in New York City. Dr. Gozani intends to provide an update on the ...
Jun 6, 2017 Waltham-based company to exhibit its wearable device for widespread chronic pain relief BOSTON--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) is showing Quell®, its 100% drug-free Wearable Pain Relief Technology™ to sleep medicine professionals from around t...
May 30, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and CEO of NeuroMetrix, is scheduled to speak at the upcoming LD Micro Invitational at the Luxe Sunset Bel Air Hotel in Los Angeles, CA. Dr. Gozani intends to provide an update on the ...
May 22, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,656,070. The patent covers the novel application of real-time accelerometer measurements to control transcutaneous electrical nerve stimulation....
May 17, 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq:NURO) announced that it was the recipient of the Smaller Businesses Association of New England (SBANE) New England Innovation Award for the development and successful launch of Quell® Wearable Pain Relief Technology™. Previous winners of this ...
Page:
2
...
20
Next Last
 
= add release to Briefcase